title: Orbital Metastases from Breast Cancer: Retrospective Analysis at an Academic Cancer Center.
abstract: Orbital metastases from breast cancer (BC) are rare, but often debilitating. BC accounts for nearly half of metastases to the orbit. Orbital metastases may be discovered years after the initial diagnosis of BC, and are rare at initial presentation. A search of the institutional data base at an academic cancer center identified BC patients who developed or presented with orbital metastases from 2000 to 2013. Baseline characteristics, treatment modalities, survival and treatment responses were collected from the electronic medical record. There were 20 patients identified with orbital metastases (0.7% of all BC cases). The median age at diagnosis of BC was 49 years; 80% had estrogen positive disease. The interval between the initial diagnosis of BC and the presentation of orbital metastases was 8.5 years (0-19 years). Orbital disease was the initial presentation of BC in two cases. Three patients developed bilateral orbital metastases and seven had accompanying brain metastases. The most common presentation was decreased vision (55%), followed by diplopia (25%). The median survival after orbital metastases was 24 months. Thirteen patients (65%) received local radiation therapy. Of those radiated, 90% reported improvement of orbital symptoms. Other treatments included intraocular bevacizumab, surgery, and systemic therapy. Orbital metastases tend to occur in estrogen receptor positive disease and are often found years after BC onset. Orbital metastases may be associated with the development of brain metastases. Radiotherapy is the preferred local therapy and had high symptom control in this cohort. Oncologists should be aware of the signs of orbital metastases and the treatment options.
authors.affiliation: Department of Internal Medicine, University of Virginia, Charlottesville, Virginia.
authors.forename: Tiffany M
authors.initials: TM
authors.lastname: Pierson
authors.affiliation: Department of Hematology-Oncology, University of Virginia, Charlottesville, Virginia.
authors.forename: Emaculate V
authors.initials: EV
authors.lastname: Tebit
authors.affiliation: Faculty, Hematology-Oncology, Charleston Area Medical Center, Charleston, West Virginia.
authors.forename: Ali
authors.initials: A
authors.lastname: El Sayed
authors.affiliation: Department of Health Sciences, University of Virginia, Charlottesville, Virginia.
authors.forename: Mark E
authors.initials: ME
authors.lastname: Smolkin
authors.affiliation: Department of Hematology-Oncology, University of Virginia, Charlottesville, Virginia.
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Dillon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D012189:Retrospective Studies; D016019:Survival Analysis
keywords: breast cancer; ocular; orbital metastases